Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
ABP | US
Overview
Corporate Details
- ISIN(s):
- US04845A1088 (+2 more)
- LEI:
- Country:
- United States of America
- Address:
- 6 ST JOHNS LANE, FLOOR 5, 10013 NEW YORK
- Website:
- https://abpro.co/
Description
Abpro Holdings, Inc. is a clinical-stage biotechnology company that develops next-generation antibody therapeutics. The company focuses on creating novel antibody constructs for challenging and high-value targets in immuno-oncology and ophthalmology. Its pipeline includes therapies targeting various cancers such as HER2-positive (HER2+) breast and gastric cancers, as well as non-HER2+ gastric, colorectal, and liver cancers. In ophthalmology, Abpro is developing treatments for conditions like wet age-related macular degeneration. The company utilizes its proprietary DiversImmune™ platform to engineer and discover its therapeutic candidates, aiming to address severe and life-threatening diseases with significant unmet medical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Abpro Holdings, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Abpro Holdings, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Abpro Holdings, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
